Bioretec Oy

Bioretec is a Finnish medical device company specializing in the design, development, and manufacturing of bioabsorbable orthopedic implants. Founded in 2003 and headquartered in Tampere, Finland, the company's mission is to leverage biology and technology to facilitate the body's natural healing processes, enabling patients to regain strength and mobility.

The company's product portfolio comprises two main lines: Activa™ and RemeOs™. Activa™ products are based on self-reinforced PLGA biopolymer and are utilized for treating small bone fractures, soft tissue lesions, and in pediatric surgery. The RemeOs™ product line, a newer generation, uses a high-performance magnesium alloy and hybrid composite, offering strong, absorbable implants designed to promote bone growth and eliminate the need for removal surgery. Bioretec's products are sold globally in approximately 40 countries, targeting the orthopedic trauma products market.

Bioretec is publicly traded on the Nasdaq First North Growth Market Finland under the ticker BRETEC. Recent developments include the RemeOs™ Trauma Screw receiving U.S. market authorization in March 2023 and CE mark approval in Europe in January 2025. Additionally, the RemeOs™ DrillPin was granted FDA Breakthrough Device Designation in December 2025. The company, led by CEO Sarah van Hellenberg Hubar-Fisher, is focused on expanding its RemeOs™ product series and establishing it as a leading absorbable metal alloy solution in the global orthopedic market.